Search Results - "ANDRADE, Jurandyr M"

Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium by Martins, Filipe Correia, Couturier, Dominique-Laurent, Paterson, Anna, Karnezis, Anthony N., Chow, Christine, Nazeran, Tayyebeh M., Odunsi, Adekunle, Gentry-Maharaj, Aleksandra, Vrvilo, Aleksandra, Hein, Alexander, Talhouk, Aline, Osorio, Ana, Hartkopf, Andreas D., Brooks-Wilson, Angela, DeFazio, Anna, Fischer, Anna, Hartmann, Arndt, Hernandez, Brenda Y., McCauley, Bryan M., Karpinskyj, Chloe, de Sousa, Christiani B., Høgdall, Claus, Tiezzi, Daniel G., Herpel, Esther, Taran, Florin Andrei, Modugno, Francesmary, Keeney, Gary, Nelson, Gregg, Steed, Helen, Song, Honglin, Luk, Hugh, Benitez, Javier, Alsop, Jennifer, Koziak, Jennifer M., Lester, Jenny, Rothstein, Joseph H., de Andrade, Jurandyr M., Lundvall, Lene, Paz-Ares, Luis, Robles-Díaz, Luis, Wilkens, Lynne R., Garcia, Maria J., Intermaggio, Maria P., Alcaraz, Marie-Lyne, Brett, Mary A., Beckmann, Matthias W., Jimenez-Linan, Mercedes, Anglesio, Michael, Carney, Michael E., Schneider, Michael, Traficante, Nadia, Pejovic, Nadja, Singh, Naveena, Le, Nhu, Sinn, Peter, Ghatage, Prafull, Erber, Ramona, Edwards, Robert, Vierkant, Robert, Ness, Roberta B., Leung, Samuel, Orsulic, Sandra, Brucker, Sara Y., Kaufmann, Scott H., Fereday, Sian, Gayther, Simon, Winham, Stacey J., Kommoss, Stefan, Pejovic, Tanja, Longacre, Teri A., McGuire, Valerie, Rhenius, Valerie, Sieh, Weiva, Shvetsov, Yurii B., Whittemore, Alice S., Staebler, Annette, Karlan, Beth Y., Rodriguez-Antona, Cristina, Bowtell, David D., Goode, Ellen L., Høgdall, Estrid, Candido dos Reis, Francisco J., Gronwald, Jacek, Chang-Claude, Jenny, Moysich, Kirsten B., Kelemen, Linda E., Cook, Linda S., Goodman, Marc T., Fasching, Peter A., Crawford, Robin, Deen, Suha, Menon, Usha, Huntsman, David G., Köbel, Martin, Ramus, Susan J., Pharoah, Paul D. P., Brenton, James D.

“…Background PTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC),…”
Get full text

IL17 Promotes Mammary Tumor Progression by Changing the Behavior of Tumor Cells and Eliciting Tumorigenic Neutrophils Recruitment by Benevides, Luciana, da Fonseca, Denise Morais, Donate, Paula Barbim, Tiezzi, Daniel Guimarães, De Carvalho, Daniel D, de Andrade, Jurandyr M, Martins, Gislaine A, Silva, João S

“…The aggressiveness of invasive ductal carcinoma (IDC) of the breast is associated with increased IL17 levels. Studying the role of IL17 in invasive breast…”
Get full text

Trastuzumab use during pregnancy: long-term survival after locally advanced breast cancer and long-term infant follow-up by Andrade, Jurandyr M de, Brito, Luiz G.O, Moises, Elaine C.D, Amorim, Andréa C, Rapatoni, Liane, Carrara, Hélio H.A, Tiezzi, Daniel G

“…Here, we describe the case of a patient diagnosed with locally advanced breast cancer 8 years ago. Her treatment course was neoadjuvant chemotherapy, followed…”
Get full text

HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination by Tiezzi, Daniel G, Andrade, Jurandyr M, Ribeiro-Silva, Alfredo, Zola, Fábio E, Marana, Heitor R C, Tiezzi, Marcelo G

“…Neoadjuvant chemotherapy has been considered the standard care in locally advanced breast cancer. However, about 20% of the patients do not benefit from this…”
Get full text

Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL‐17A expression and invasiveness of the tumor by Benevides, Luciana, Cardoso, Cristina R. B., Tiezzi, Daniel G., Marana, Heitor R. C., Andrade, Jurandyr M., Silva, João S.

“…Breast cancer is a leading cause of neoplasia‐associated death in women worldwide. Regulatory T (Treg) and Th17 cells are enriched within some tumors, but the…”
Get full text

DNA repair genes XRCC1 and XRCC3 polymorphisms and their relationship with the level of micronuclei in breast cancer patients by Santos, Raquel A, Teixeira, Ana Claudia, Mayorano, Monica B, Carrara, Helio H A, Andrade, Jurandyr M, Takahashi, Catarina S

“…Breast cancer (BC) is the most prevalent type worldwide, besides being one of the most common causes of death among women. It has been suggested that sporadic…”
Get full text

Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods by Oliveira, Tatiane M. G., Elias, Jorge, Melo, Andrea F., Teixeira, Sara R., Filho, Salomão C., Gonçalves, Larissa M., Faria, Francesca M., Tiezzi, Daniel G., Andrade, Jurandyr M., Muglia, Valdair

“…Invasive lobular carcinoma (ILC) and lobular neoplasia (LN) are two distinct conditions that still pose challenges regarding to their classification, diagnosis…”
Get full text

Hysteroscopic appearance of malignant and benign endometrial lesions: a case-control study by Zola, Fábio E, Nogueira, Antonio A, de Andrade, Jurandyr M, Candido dos Reis, Francisco J

“…To analyze hysteroscopic appearance of benign and malignant endometrial lesions in order to identify patterns to estimate the risk of malignance. Matched…”
Get full text

Basal levels of DNA damage detected by micronuclei and comet assays in untreated breast cancer patients and healthy women by Santos, Raquel A., Teixeira, Ana Cláudia, Mayorano, Monica B., Carrara, Hélio H. A., Andrade, Jurandyr M., Takahashi, Catarina S.

“…Breast cancer is the second most frequent type of cancer worldwide and is the most common malignant disease among women. Risk factors for breast cancer include…”
Get full text

HIF-1α and locally advanced breast cancer by Marana, Heitor R C, Tiezze, Daniel G, de Andrade, Jurandyr M, da Silva, João S

Get more information

Cytology for the detection of early recurrence of gynecologic cancer in the vaginal vault by Lara, Lucia A S, de Andrade, Jurandyr M, Dos Reis, Francisco J C

“…The real benefit of follow-up cervical cytology in women treated for gynecological cancer is unclear. This study was designed to assess the rate of success of…”
Get more information

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer by Goode, Ellen L, Block, Matthew S, Kalli, Kimberly R, Vierkant, Robert A, Chen, Wenqian, Fogarty, Zachary C, Gentry-Maharaj, Aleksandra, Tołoczko, Aleksandra, Hein, Alexander, Bouligny, Aliecia L, Jensen, Allan, Osorio, Ana, Hartkopf, Andreas, Ryan, Andy, Chudecka-Głaz, Anita, Magliocco, Anthony M, Hartmann, Arndt, Jung, Audrey Y, Gao, Bo, Hernandez, Brenda Y, Fridley, Brooke L, McCauley, Bryan M, Kennedy, Catherine J, Wang, Chen, Karpinskyj, Chloe, de Sousa, Christiani B, Tiezzi, Daniel G, Wachter, David L, Herpel, Esther, Taran, Florin Andrei, Modugno, Francesmary, Nelson, Gregg, Lubiński, Jan, Menkiszak, Janusz, Alsop, Jennifer, Lester, Jenny, García-Donas, Jesús, Nation, Jill, Hung, Jillian, Palacios, José, Rothstein, Joseph H, Kelley, Joseph L, de Andrade, Jurandyr M, Robles-Díaz, Luis, Intermaggio, Maria P, Widschwendter, Martin, Beckmann, Matthias W, Ruebner, Matthias, Jimenez-Linan, Mercedes, Singh, Naveena, Oszurek, Oleg, Harnett, Paul R, Rambau, Peter F, Sinn, Peter, Wagner, Philipp, Ghatage, Prafull, Sharma, Raghwa, Edwards, Robert P, Ness, Roberta B, Orsulic, Sandra, Brucker, Sara Y, Johnatty, Sharon E, Longacre, Teri A, Ursula, Eilber, McGuire, Valerie, Sieh, Weiva, Natanzon, Yanina, Li, Zheng, Whittemore, Alice S, Anna, deFazio, Staebler, Annette, Karlan, Beth Y, Gilks, Blake, Bowtell, David D, Høgdall, Estrid, Candido dos Reis, Francisco J, Steed, Helen, Campbell, Ian G, Gronwald, Jacek, Benítez, Javier, Koziak, Jennifer M, Chang-Claude, Jenny, Moysich, Kirsten B, Kelemen, Linda E, Cook, Linda S, Goodman, Marc T, García, María José, Fasching, Peter A, Kommoss, Stefan, Deen, Suha, Kjaer, Susanne K, Menon, Usha, Brenton, James D, Pharoah, Paul DP, Chenevix-Trench, Georgia, Huntsman, David G, Winham, Stacey J, Köbel, Martin, Ramus, Susan J

“…Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic…”
Get more information

Abstract PS9-27: Estimation of clinical benefit and economic burden for using a commercial 70-gene signature test for Brazilian breast cancer patients in the public health system by Pimentel, Franklin F, Buzatto, Isabela PC, Rodrigues, Tamara CGF, Borba, Jessica MC, Peruchi, Karoline PI, de Andrade, Jurandyr M, Tiezzi, Daniel G

“…Background The clinical benefit of adjuvant chemotherapy (CT) for breast cancer (BC) depends on several factors, like menopausal status, stage and molecular…”
Get full text

Abstract P2-08-31: Role of body mass index in Brazilian breast cancer patients: Clinical-pathological characteristics and outcome in a single-institution retrospective cohort by Orlandini, Leonardo F, Pimentel, Franklin F, Carrara, Hélio HA, dos Reis, Francisco JC, de Andrade, Jurandyr M, Tiezzi, Daniel G

“…Background: Despite of several studies described body mass index (BMI) as a poor prognostic factor in breast cancer (BC) patients, the available data are still…”
Get full text

Abstract P5-05-08: Comparative evaluation of a trastuzumab biosimilar or originator trastuzumab in association with pertuzumab: Binding and biological activities in cell culture-based assays by Pimentel, Franklin F, Toledo, Juliano S, Gonçalves, João, Alves, Leandro L, de Paula, Mayara I, de Andrade, Jurandyr M, Tiezzi, Daniel G, Chammas, Roger

“…Background: trastuzumab (TZB) is approved for the treatment of HER2-positive (HER2+) breast cancer in different indications and schemes. The association of…”
Get full text

Abstract P2-08-22: Adjuvant trastuzumab effectiveness in a cohort of HER2-positive breast cancer Brazilian patients treated in a public hospital: The impact in public health planning compared to clinical trial data by Orlandini, Leonardo F, Pimentel, Franklin F, Carrara, Hélio HA, Reis, Francisco JC dos, de Andrade, Jurandyr M, Tiezzi, Daniel G

“…Background: About 20% of breast cancer (BC) subtypes are classified as HER2-positive (HER2+), recognized as a biomarker for worse prognosis. Trastuzumab (T) is…”
Get full text

Abstract PS13-30: Evaluation of factors related to efficacy and safety of neo/adjuvant chemotherapy for breast cancer as a brief estimate of the impact of COVID-19 pandemic by Pimentel, Franklin F, Borba, Jessica MC, Rodrigues, Tamara CGF, Peruchi, Karoline PI, Carrara, Helio HA, de Andrade, Jurandyr M, Candido dos Reis, Francisco J

“…Background COVID-19 pandemic presented as a challenge to breast cancer (BC) treatment, especially considering safety concerns and resource scarcity. Treatment…”
Get full text

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer by Winham, Stacey J., Traficante, Nadia, Tołoczko, Aleksandra, Tiezzi, Daniel G., Sinn, Peter, Rothstein, Joseph H., Paz-Ares, Luis, Oszurek, Oleg, Orsulic, Sandra, Nelson, Gregg, Menkiszak, Janusz, Longacre, Teri A., Li, Zheng, Lester, Jenny, Kennedy, Catherine J., Kalli, Kimberly R., Johnatty, Sharon E., Jensen, Allan, Hung, Jillian, Herpel, Esther, Hernandez, Brenda Y., Hartkopf, Andreas D., de Andrade, Jurandyr M., Chudecka-Głaz, Anita, Brucker, Sara Y., Bowtell, D., Webb, P., Gertig, D., Fereday, S., Moore, S., Harrap, K., Pandeya, N., Malt, M., Mellon, A., Robertson, R., Vanden Bergh, T., Brown, S., Green, L., Ferguson, K., Martyn, A., Ball, C., Bilic, Sanela, Stuart-Harris, R., Glasgow, A., Proietto, A., Braye, S., Shannon, J., Ferrier, A., Nevell, D., Valmadre, S., Young, B., Crouch, R., Robertson, G., Carter, J., Dalrymple, C., Houghton, R., Grygiel, J., Jaworski, R., Harnett, P., Wain, G., Papadimos, D., Crandon, A., Cummings, M., Horwood, K., Obermair, A., Davy, M., Dodd, T., Henderson, D., Pierdes, J., Brown, B., Allen, D., Grant, P., Robbie, M., Healy, D., Jobling, T., McNealage, J., Fox, S., Lade, S., Loughrey, M., O'Callaghan, N., Murray, W., Neesham, D., Bell, R., Ganju, V., Buck, M., Whiteman, D., Whittemore, Alice S., Steed, Helen, Kjaer, Susanne K., Kelemen, Linda E., Karlan, Beth Y., Huntsman, David G., Høgdall, Estrid, Gronwald, Jacek, Fasching, Peter A., Chang-Claude, Jenny, Campbell, Ian G., Pharoah, Paul D.P., Ramus, Susan J., Goode, Ellen L.

“…To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in relation to clinical features of epithelial…”
Get full text

IL-17 Promotes Mammary Tumor Progression by Changing the Behavior of Tumor Cells and Eliciting Tumorigenic Neutrophils Recruitment by Benevides, Luciana, da Fonseca, Denise Morais, Donate, Paula Barbim, Tiezzi, Daniel Guimarães, De Carvalho, Daniel D, de Andrade, Jurandyr M, Martins, Gislâine A, Silva, João S

“…The aggressiveness of invasive ductal carcinoma (IDC) of the breast is associated with increased IL17 levels. Studying the role of IL17 in invasive breast…”
Get full text

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study by Rambau, Peter F, Vierkant, Robert A, Intermaggio, Maria P, Kelemen, Linda E, Goodman, Marc T, Herpel, Esther, Pharoah, Paul D, Kommoss, Stefan, Jimenez‐Linan, Mercedes, Karlan, Beth Y, Gentry‐Maharaj, Aleksandra, Menon, Usha, Polo, Susanna Hernando, Candido dos Reis, Francisco J, Doherty, Jennifer Anne, Gayther, Simon A, Sharma, Raghwa, Larson, Melissa C, Harnett, Paul R, Hatfield, Emma, de Andrade, Jurandyr M, Nelson, Gregg S, Steed, Helen, Schildkraut, Joellen M, Carney, Micheal E, Høgdall, Estrid, Whittemore, Alice S, Widschwendter, Martin, Kennedy, Catherine J, Wang, Frances, Wang, Qin, Wang, Chen, Armasu, Sebastian M, Daley, Frances, Coulson, Penny, Jones, Micheal E, Anglesio, Micheal S, Chow, Christine, de Fazio, Anna, García‐Closas, Montserrat, Brucker, Sara Y, Cybulski, Cezary, Harris, Holly R, Hartkopf, Andreas D, Huzarski, Tomasz, Jensen, Allan, Lubiński, Jan, Oszurek, Oleg, Benitez, Javier, Mina, Fady, Staebler, Annette, Taran, Florin Andrei, Pasternak, Jana, Talhouk, Aline, Rossing, Mary Anne, Hendley, Joy, Edwards, Robert P, Fereday, Sian, Modugno, Francesmary, Ness, Roberta B, Sieh, Weiva, El‐Bahrawy, Mona A, Winham, Stacey J, Lester, Jenny, Kjaer, Susanne K, Gronwald, Jacek, Sinn, Peter, Fasching, Peter A, Chang‐Claude, Jenny, Moysich, Kirsten B, Bowtell, David D, Hernandez, Brenda Y, Luk, Hugh, Behrens, Sabine, Shah, Mitul, Jung, Audrey, Ghatage, Prafull, Alsop, Jennifer, Alsop, Kathryn, García‐Donas, Jesús, Thompson, Pamela J, Swerdlow, Anthony J, Karpinskyj, Chloe, Cazorla‐Jiménez, Alicia, García, María J, Deen, Susha, Wilkens, Lynne R, Palacios, José, Berchuck, Andrew, Koziak, Jennifer M, Brenton, James D, Cook, Linda S, Goode, Ellen L, Huntsman, David G, Ramus, Susan J, Köbel, Martin

“…We aimed to validate the prognostic association of p16 expression in ovarian high‐grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma…”
Get full text